Roth MKM Initiates Coverage On Unity Biotechnology with Buy Rating, Announces Price Target of $10
Portfolio Pulse from richadhand@benzinga.com
Roth MKM analyst Dylan Dupuis initiates coverage on Unity Biotechnology (NASDAQ:UBX) with a Buy rating and announces a price target of $10.
May 31, 2023 | 8:27 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Unity Biotechnology receives a Buy rating from Roth MKM analyst Dylan Dupuis, with a price target of $10.
The Buy rating and price target announcement by Roth MKM analyst Dylan Dupuis is a positive signal for Unity Biotechnology (UBX). This recommendation suggests that the analyst believes the stock has potential for growth in the short term, which could lead to an increase in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100